DiMinno G, Silver M J, Cerbone A M, Murphy S
Blood. 1986 Oct;68(4):886-91.
We compared the ability of aspirin to suppress platelet aggregation and thromboxane synthesis in ten normal subjects and ten patients with diabetic angiopathy and high rate of entry of new platelets into the circulation. When single doses of 100 to 1,000 mg aspirin were ingested daily for 1 month, there were time gaps between doses in which platelets from diabetics and normals aggregated and formed thromboxane ex vivo in response to the combination of arachidonic acid plus collagen. Similar gaps were also found for diabetics, but not for normals, following four daily doses (every six hours) of 25 or 100 mg. Our data show that dose schedules of aspirin which may suffice in normals are not effective in patients with diabetic angiopathy, presumably because these patients have a high rate of entry of new platelets into the circulation. We suggest that continual suppression of platelet thromboxane synthesis and aggregation by low-dose, "slow-release" preparations of aspirin would be an ideal long-term approach for the prevention of thrombosis in patients with a high rate of entry of new platelets into the circulation.
我们比较了阿司匹林对10名正常受试者以及10名患有糖尿病性血管病且新血小板进入循环速率较高的患者的血小板聚集和血栓素合成的抑制能力。当每日单次服用100至1000毫克阿司匹林，持续1个月时，在剂量间隔期，糖尿病患者和正常受试者的血小板会在体外因花生四烯酸与胶原蛋白的组合而聚集并形成血栓素。在每日四次（每六小时一次）服用25毫克或100毫克阿司匹林后，糖尿病患者也出现了类似的间隔期，但正常受试者未出现。我们的数据表明，对正常受试者足够的阿司匹林给药方案对糖尿病性血管病患者无效，可能是因为这些患者新血小板进入循环的速率较高。我们建议，通过低剂量“缓释”阿司匹林制剂持续抑制血小板血栓素合成和聚集，对于预防新血小板进入循环速率较高的患者发生血栓形成而言，将是一种理想的长期方法。
